{"id":8826,"date":"2026-02-09T12:55:43","date_gmt":"2026-02-09T12:55:43","guid":{"rendered":"https:\/\/blog.mygenericpharmacy.com\/?p=8826"},"modified":"2026-02-09T12:55:47","modified_gmt":"2026-02-09T12:55:47","slug":"immunotherapy-revolution-harnessing-the-bodys-defense-system-to-fight-disease","status":"publish","type":"post","link":"https:\/\/blog.mygenericpharmacy.com\/index.php\/2026\/02\/09\/immunotherapy-revolution-harnessing-the-bodys-defense-system-to-fight-disease\/","title":{"rendered":"Immunotherapy Revolution: Harnessing the Body&#8217;s Defense System to Fight Disease"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\"><strong>A Paradigm Shift in Medicine<\/strong><\/h3>\n\n\n\n<p>Immunotherapy represents a groundbreaking frontier in medical science\u2014a treatment approach that doesn&#8217;t directly target diseases but instead empowers the body&#8217;s own immune system to combat them. While traditional therapies like chemotherapy attack both healthy and diseased cells, immunotherapy specifically trains, enhances, or redirects our natural defenses. This approach has revolutionized cancer treatment and holds transformative promise for autoimmune disorders, infectious diseases, and even neurodegenerative conditions. The 2018 Nobel Prize in Physiology or Medicine awarded to James Allison and Tasuku Honjo for their discoveries in cancer immunotherapy underscores its monumental importance.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><a href=\"https:\/\/my.clevelandclinic.org\/health\/body\/21196-immune-system\" target=\"_blank\" rel=\"noopener\" title=\"The Immune System: A Complex Defense Network\">The Immune System: A Complex Defense Network<\/a><\/strong><\/h3>\n\n\n\n<p>To understand immunotherapy, we must first appreciate the immune system&#8217;s sophisticated architecture:<\/p>\n\n\n\n<p><strong>Innate Immunity:<\/strong>&nbsp;Our rapid-response first line of defense including physical barriers (skin), phagocytes (neutrophils, macrophages), and natural killer (NK) cells.<\/p>\n\n\n\n<p><strong>Adaptive Immunity:<\/strong>&nbsp;The specialized, learned response involving:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T-cells:<\/strong>\u00a0Orchestrate immune responses; include\u00a0<strong>cytotoxic T-cells<\/strong>\u00a0(CD8+) that kill infected\/cancerous cells, and\u00a0<strong>helper T-cells<\/strong>\u00a0(CD4+) that direct the immune orchestra.<\/li>\n\n\n\n<li><strong>B-cells:<\/strong>\u00a0Produce antibodies that neutralize pathogens.<\/li>\n\n\n\n<li><strong>Memory cells:<\/strong>\u00a0Provide long-term immunity.<\/li>\n<\/ul>\n\n\n\n<p><strong>Immune Checkpoints:<\/strong>&nbsp;Crucial regulatory molecules (like PD-1, CTLA-4) that prevent excessive immune responses and autoimmunity\u2014a mechanism cancers exploit to evade detection.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1074761313002963\" target=\"_blank\" rel=\"noopener\" title=\"The Cancer-Immunity Cycle: Where Immunotherapy Intervenes\">The Cancer-Immunity Cycle: Where Immunotherapy Intervenes<\/a><\/strong><\/h3>\n\n\n\n<p>Cancer develops when malignant cells evade immune surveillance. The&nbsp;<strong>cancer-immunity cycle<\/strong>&nbsp;describes the seven-step process required for an effective anti-tumor response [2]:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Release of cancer cell antigens<\/strong><\/li>\n\n\n\n<li><strong>Antigen presentation<\/strong>\u00a0by dendritic cells<\/li>\n\n\n\n<li><strong>Priming and activation<\/strong>\u00a0of T-cells<\/li>\n\n\n\n<li><strong>Trafficking of T-cells<\/strong>\u00a0to tumors<\/li>\n\n\n\n<li><strong>Infiltration into the tumor microenvironment<\/strong><\/li>\n\n\n\n<li><strong>Recognition of cancer cells<\/strong>\u00a0by T-cells<\/li>\n\n\n\n<li><strong>Killing of cancer cells<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Each step presents a potential therapeutic target. Immunotherapy works by removing barriers and amplifying signals along this cycle.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><a href=\"https:\/\/www.cancerresearch.org\/immunotherapy-by-treatment-types\" target=\"_blank\" rel=\"noopener\" title=\"Types of Immunotherapy: The Therapeutic Arsenal\">Types of Immunotherapy: The Therapeutic Arsenal<\/a><\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>1. Immune Checkpoint Inhibitors (The Game-Changers)<\/strong><\/h4>\n\n\n\n<p>These drugs block proteins that act as immune system &#8220;brakes,&#8221; unleashing T-cells to attack cancer.<\/p>\n\n\n\n<p><strong>PD-1\/PD-L1 Inhibitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong>\u00a0Programmed Death-1 (PD-1) on T-cells binds to PD-L1 on cancer cells, signaling &#8220;don&#8217;t attack me.&#8221; Blocking this interaction removes the disguise.<\/li>\n\n\n\n<li><strong>Drugs:<\/strong>\u00a0Pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq).<\/li>\n\n\n\n<li><strong>Success story:<\/strong>\u00a0Transformed advanced melanoma (5-year survival increased from 5% to 52% with ipilimumab+nivolumab) [3].<\/li>\n<\/ul>\n\n\n\n<p><strong>CTLA-4 Inhibitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong>\u00a0Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) regulates early T-cell activation.<\/li>\n\n\n\n<li><strong>Drug:<\/strong>\u00a0Ipilimumab (Yervoy).<\/li>\n\n\n\n<li><strong>Notable:<\/strong>\u00a0First checkpoint inhibitor approved (2011 for melanoma).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2. CAR T-Cell Therapy: Living Drugs<\/strong><\/h4>\n\n\n\n<p>Chimeric Antigen Receptor (CAR) T-cell therapy genetically engineers a patient&#8217;s own T-cells to recognize and destroy cancer.<\/p>\n\n\n\n<p><strong>Process:<\/strong><\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Leukapheresis:<\/strong>\u00a0Collect patient T-cells.<\/li>\n\n\n\n<li><strong>Genetic engineering:<\/strong>\u00a0Insert CAR gene targeting a tumor antigen (e.g., CD19 for B-cell cancers).<\/li>\n\n\n\n<li><strong>Expansion:<\/strong>\u00a0Grow millions of CAR T-cells.<\/li>\n\n\n\n<li><strong>Lymphodepleting chemotherapy:<\/strong>\u00a0Clear space in immune system.<\/li>\n\n\n\n<li><strong>Infusion:<\/strong>\u00a0Return &#8220;supercharged&#8221; T-cells to patient.<\/li>\n<\/ol>\n\n\n\n<p><strong>Approved therapies:<\/strong>&nbsp;Tisagenlecleucel (Kymriah) for leukemia\/lymphoma, axicabtagene ciloleucel (Yescarta).<\/p>\n\n\n\n<p><strong>Remarkable results:<\/strong>&nbsp;80-90% complete remission in refractory B-cell ALL [4].<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>3. Cancer Vaccines<\/strong><\/h4>\n\n\n\n<p>Unlike preventive vaccines, therapeutic cancer vaccines train the immune system to recognize tumor-specific antigens.<\/p>\n\n\n\n<p><strong>Types:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dendritic cell vaccines:<\/strong>\u00a0Sipuleucel-T (Provenge) for prostate cancer\u2014first FDA-approved cancer vaccine (2010).<\/li>\n\n\n\n<li><strong>Neoantigen vaccines:<\/strong>\u00a0Personalized vaccines targeting patient-specific tumor mutations.<\/li>\n\n\n\n<li><strong>Virus-based vaccines:<\/strong>\u00a0Talimogene laherparepvec (T-VEC) uses modified herpes virus to infect melanoma cells, triggering immune response.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>4. Monoclonal Antibodies<\/strong><\/h4>\n\n\n\n<p>Lab-created antibodies that either:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mark cancer cells<\/strong>\u00a0for immune destruction (rituximab targets CD20 on lymphoma cells).<\/li>\n\n\n\n<li><strong>Deliver toxins\/radiation<\/strong>\u00a0directly to tumors (antibody-drug conjugates like ado-trastuzumab emtansine for HER2+ breast cancer).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>5. Cytokines: Immune System Messengers<\/strong><\/h4>\n\n\n\n<p>Proteins that regulate immune cell activity:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Interleukin-2 (IL-2):<\/strong>\u00a0For metastatic melanoma\/renal cancer (limited by toxicity).<\/li>\n\n\n\n<li><strong>Interferon-alpha:<\/strong>\u00a0Historical use in melanoma, now largely supplanted.<\/li>\n\n\n\n<li><strong>Newer cytokines:<\/strong>\u00a0Engineered versions with improved safety profiles.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>6. Oncolytic Virus Therapy<\/strong><\/h4>\n\n\n\n<p>Genetically modified viruses that selectively infect and kill cancer cells while stimulating immune responses. T-VEC (mentioned above) is the first FDA-approved oncolytic virus.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12061710\/\" target=\"_blank\" rel=\"noopener\" title=\"Beyond Cancer: Immunotherapy's Expanding Horizons\">Beyond Cancer: Immunotherapy&#8217;s Expanding Horizons<\/a><\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Autoimmune Diseases<\/strong><\/h4>\n\n\n\n<p>Paradoxically, here the goal is to&nbsp;<strong>suppress<\/strong>&nbsp;overactive immune responses:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Checkpoint agonists:<\/strong>\u00a0Activate inhibitory pathways (experimental for lupus, rheumatoid arthritis).<\/li>\n\n\n\n<li><strong>Treg (regulatory T-cell) therapy:<\/strong>\u00a0Expand these &#8220;peacekeeper&#8221; cells.<\/li>\n\n\n\n<li><strong>B-cell depletion:<\/strong>\u00a0Rituximab for rheumatoid arthritis, lupus.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Infectious Diseases<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HIV:<\/strong>\u00a0Broadly neutralizing antibodies in clinical trials.<\/li>\n\n\n\n<li><strong>COVID-19:<\/strong>\u00a0Monoclonal antibodies (bamlanivimab, REGEN-COV) for prevention\/treatment.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Neurodegenerative Diseases<\/strong><\/h4>\n\n\n\n<p>Early research using antibodies to clear pathological proteins:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong><a href=\"https:\/\/mygenericpharmacy.com\/category\/products\/disease\/alzheimer-disease\" target=\"_blank\" rel=\"noopener\" title=\"Alzheimer's\">Alzheimer&#8217;s<\/a>:<\/strong>\u00a0Aducanumab targets amyloid-beta plaques.<\/li>\n\n\n\n<li><strong><a href=\"https:\/\/mygenericpharmacy.com\/category\/products\/disease\/parkinsons-disease\" target=\"_blank\" rel=\"noopener\" title=\"Parkinson's\">Parkinson&#8217;s<\/a>:<\/strong>\u00a0Antibodies targeting alpha-synuclein.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Transplant Medicine<\/strong><\/h4>\n\n\n\n<p>Treg therapy to promote transplant tolerance, reducing need for lifelong immunosuppression.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The Challenges and Limitations<\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Response Heterogeneity<\/strong><\/h4>\n\n\n\n<p>Immunotherapy doesn&#8217;t work for everyone. Biomarkers help predict response:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tumor mutational burden (TMB):<\/strong>\u00a0Higher mutations \u2192 more neoantigens \u2192 better response.<\/li>\n\n\n\n<li><strong>PD-L1 expression:<\/strong>\u00a0Higher expression often predicts checkpoint inhibitor response.<\/li>\n\n\n\n<li><strong>Mismatch repair deficiency (dMMR):<\/strong>\u00a0Predicts pembrolizumab response across cancers.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Immune-Related Adverse Events (irAEs)<\/strong><\/h4>\n\n\n\n<p>Unleashing the immune system can cause autoimmunity-like side effects affecting any organ:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Colitis:<\/strong>\u00a0Diarrhea, abdominal pain (most common with CTLA-4 inhibitors).<\/li>\n\n\n\n<li><strong>Pneumonitis:<\/strong>\u00a0Cough, shortness of breath.<\/li>\n\n\n\n<li><strong>Endocrinopathies:<\/strong>\u00a0Thyroiditis, hypophysitis, diabetes.<\/li>\n\n\n\n<li><strong>Dermatitis:<\/strong>\u00a0Rash, pruritus.<\/li>\n\n\n\n<li><strong>Hepatitis, nephritis, myocarditis.<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Management:<\/strong>&nbsp;High-dose corticosteroids, other immunosuppressants, treatment interruption\/discontinuation.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Resistance Mechanisms<\/strong><\/h4>\n\n\n\n<p>Tumors develop resistance through:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Loss of antigen presentation.<\/li>\n\n\n\n<li>Upregulation of alternative checkpoints.<\/li>\n\n\n\n<li>Creating immunosuppressive tumor microenvironment.<\/li>\n\n\n\n<li>T-cell exhaustion.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Logistical and Financial Barriers<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CAR T-cell therapy:<\/strong>\u00a0Complex manufacturing, &#8220;vein-to-vein&#8221; time ~3 weeks, cost ~$400,000.<\/li>\n\n\n\n<li><strong>Checkpoint inhibitors:<\/strong>\u00a0$100,000-$150,000\/year.<\/li>\n\n\n\n<li><strong>Access disparities:<\/strong>\u00a0Limited to major academic centers, insurance barriers.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The Future Frontier: Next-Generation Immunotherapies<\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Novel Targets<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TIM-3, LAG-3, TIGIT:<\/strong>\u00a0Next-generation checkpoint inhibitors.<\/li>\n\n\n\n<li><strong>CD47:<\/strong>\u00a0&#8220;Don&#8217;t eat me&#8221; signal on cancer cells; magrolimab blocks it, enhancing phagocytosis.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Combination Strategies<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunotherapy + targeted therapy:<\/strong>\u00a0BRAF\/MEK inhibitors + checkpoint inhibitors in melanoma.<\/li>\n\n\n\n<li><strong>Immunotherapy + chemotherapy:<\/strong>\u00a0Synergistic effect (pembrolizumab+chemotherapy in lung cancer).<\/li>\n\n\n\n<li><strong>Dual checkpoint blockade:<\/strong>\u00a0CTLA-4 + PD-1 inhibitors (increased efficacy but also toxicity).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Technological Innovations<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Off-the-shelf CAR T-cells:<\/strong>\u00a0From healthy donors (allogeneic), avoiding manufacturing delays.<\/li>\n\n\n\n<li><strong>CAR NK cells:<\/strong>\u00a0Natural killer cells with CARs\u2014potentially safer.<\/li>\n\n\n\n<li><strong>Bi-specific T-cell engagers (BiTEs):<\/strong>\u00a0Antibodies connecting T-cells to cancer cells (blinatumomab for ALL).<\/li>\n\n\n\n<li><strong>TCR therapy:<\/strong>\u00a0T-cell receptors engineered to recognize intracellular antigens (broader than CARs).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Personalized Approaches<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neoantigen vaccines:<\/strong>\u00a0Tailored to patient&#8217;s tumor mutation profile.<\/li>\n\n\n\n<li><strong>Tumor-infiltrating lymphocyte (TIL) therapy:<\/strong>\u00a0Expand naturally occurring tumor-fighting T-cells.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Patient Experience and Practical Considerations<\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Treatment Journey<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pretesting:<\/strong>\u00a0Biomarker analysis (PD-L1, TMB, MSI), organ function tests.<\/li>\n\n\n\n<li><strong>Administration:<\/strong>\u00a0Most immunotherapies are IV infusions every 2-6 weeks.<\/li>\n\n\n\n<li><strong>Monitoring:<\/strong>\u00a0Regular imaging (CT\/PET scans), blood tests, vigilance for irAEs.<\/li>\n\n\n\n<li><strong>Response patterns:<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Hyperprogression:<\/strong>\u00a0Rare rapid worsening.<\/li>\n\n\n\n<li><strong>Pseudoprogression:<\/strong>\u00a0Apparent tumor growth from immune infiltration before shrinkage.<\/li>\n\n\n\n<li><strong>Delayed response:<\/strong>\u00a0Can occur months after starting.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Lifestyle and Support<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diet\/exercise:<\/strong>\u00a0Emerging evidence supports Mediterranean diet, regular activity.<\/li>\n\n\n\n<li><strong>Microbiome:<\/strong>\u00a0Gut bacteria may influence response (fecal microbiota transplantation trials ongoing).<\/li>\n\n\n\n<li><strong>Support networks:<\/strong>\u00a0Critical for navigating complex treatment and side effects.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Conclusion: A Transformative Era in Medicine<\/strong><\/h3>\n\n\n\n<p>Immunotherapy has fundamentally altered the therapeutic landscape, particularly in oncology, offering durable responses and even cures in previously untreatable advanced cancers. Beyond remarkable clinical successes, it represents a conceptual revolution\u2014viewing disease not just as something to attack, but as a failure of natural defenses that can be corrected.<\/p>\n\n\n\n<p>The field is advancing at breathtaking speed, with over 3,000 immunotherapy clinical trials currently active worldwide. Challenges remain\u2014improving response rates, managing toxicities, reducing costs, and expanding access\u2014yet the trajectory is unmistakably toward increasingly sophisticated, personalized, and effective immune-based treatments.<\/p>\n\n\n\n<p>As we decode more complexities of immune regulation, immunotherapy promises to extend its reach across medicine, offering hope for conditions once considered intractable. This is more than a new class of drugs\u2014it&#8217;s a new paradigm for healing, harnessing the most sophisticated defense system ever evolved: our own immunity.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>References:<\/strong><br><strong><a href=\"https:\/\/my.clevelandclinic.org\/health\/body\/21196-immune-system\" target=\"_blank\" rel=\"noopener\" title=\"\">https:\/\/my.clevelandclinic.org\/health\/body\/21196-immune-system<br><\/a><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1074761313002963\n\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1074761313002963<br><\/a><a href=\"https:\/\/www.cancerresearch.org\/immunotherapy-by-treatment-types\" target=\"_blank\" rel=\"noopener\" title=\"\">https:\/\/www.cancerresearch.org\/immunotherapy-by-treatment-types<br><\/a><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12061710\/\" target=\"_blank\" rel=\"noopener\" title=\"\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12061710\/<\/a><\/strong><\/p>\n\n\n\n<p>Medications that have been suggested by doctors worldwide are available on the link below<br><strong><a href=\"https:\/\/mygenericpharmacy.com\/category\/products\/disease\/parkinsons-disease\" target=\"_blank\" rel=\"noopener\" title=\"\">https:\/\/mygenericpharmacy.com\/category\/products\/disease\/parkinsons-disease<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Paradigm Shift in Medicine Immunotherapy represents a groundbreaking frontier in medical science\u2014a treatment approach that doesn&#8217;t directly target diseases but instead empowers the body&#8217;s own immune system to combat them. While traditional therapies like chemotherapy attack both healthy and diseased cells, immunotherapy specifically trains, enhances, or redirects our natural defenses. This approach has revolutionized cancer treatment and holds transformative promise for autoimmune disorders, infectious diseases, and even neurodegenerative conditions. The 2018 Nobel Prize in Physiology or Medicine awarded to&#8230;<\/p>\n<p class=\"read-more\"><a class=\"btn btn-default\" href=\"https:\/\/blog.mygenericpharmacy.com\/index.php\/2026\/02\/09\/immunotherapy-revolution-harnessing-the-bodys-defense-system-to-fight-disease\/\"> Read More<span class=\"screen-reader-text\">  Read More<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[3629,407],"tags":[],"class_list":["post-8826","post","type-post","status-publish","format-standard","hentry","category-alzheimer","category-immune-system"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/8826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/comments?post=8826"}],"version-history":[{"count":1,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/8826\/revisions"}],"predecessor-version":[{"id":8827,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/8826\/revisions\/8827"}],"wp:attachment":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/media?parent=8826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/categories?post=8826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/tags?post=8826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}